Intellia Therapeutics, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts. Founded in 2014, the company specializes in developing innovative therapeutics using CRISPR-based technologies. Its mission is to transform medicine by utilizing the CRISPR/Cas9 system to edit disease-associated genes, providing potential treatments for chronic diseases. The company has both in vivo and ex vivo programs. In vivo programs involve CRISPR therapies administered intravenously to edit genes directly within target tissues, focusing on liver diseases like alpha-1 antitrypsin deficiency and primary hyperoxaluria Type 1. Ex vivo programs engineer human cells for therapies aimed at cancer and autoimmune diseases, including hematopoietic stem cells and CAR-T cells. Notable pipeline products include NTLA-2001, NTLA-2002, NTLA-2003, and NTLA-3001. Intellia Therapeutics collaborates with several leading biotechnology companies, such as Novartis and Regeneron, to advance its research and development efforts.